Krueppel-like factor 1 (KLF1)

Krueppel-like factor 1 (KLF1) is an erythroid-specific transcription factor belonging to the Krueppel-like factor family, characterized by a highly conserved C-terminal DNA-binding domain composed of three C2H2 zinc finger motifs[2][3][4]. KLF1 is a master regulator of erythroid lineage commitment and terminal erythropoiesis, playing a crucial role in activating adult β-globin expression, repressing γ-globin via BCL11A induction, and orchestrating global erythroid gene expression—including proteins involved in red cell structure, metabolism, membrane integrity, cell cycle, and apoptosis[2][3][4]. Mutations in KLF1 can result in a spectrum of hereditary red blood cell disorders, from benign phenotypes (such as increased fetal hemoglobin) to severe anemias (notably β-thalassemia-like diseases)[2]. While no approved drugs currently target KLF1 directly, its central role in hemoglobin switching and erythroid differentiation makes it an attractive target for gene-based therapies aimed at treating β-hemoglobinopathies and sickle cell disease[2][5]. Disruption of KLF1 function can lead to severe anemia and defective red cell development[3][4].

Other names

Krueppel-like factor 1EKLFErythroid Krueppel-like factorerythroid-specific transcription factor EKLFCDAN4ACDAN4BEKLF/KLF1erythroid Krüppel-like transcription factor

Not directly druggable at present; genetic or epigenetic modulation (e.g., gene editing, gene silencing, or artificial repressors/activators) proposed to alter erythropoiesis or hemoglobin switching[2][5]